Full history for every metric is available with a Kvantra account
Achilles Therapeutics plc (ACHL)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -75 | -72 | |||||
| Net profit | $m | -7 | -14 | -33 | -61 | -71 | -70 | -67 |
| EPS reported | $ | -1.74 | -1.66 | |||||
| Operating cashflow per share | $ | -1.21 | -1.21 | |||||
| Capex per share | $ | 0.03 | 0.03 | |||||
| FCF per share | $ | -1.24 | -1.24 | |||||
| Free cash flow | $m | -50 | -31 | |||||
| Net debt | $m | -132 | -86 | |||||
| Book value equity | $m | 142 | 103 | |||||
| Book value per share | $ | 3.56 | 2.55 | |||||
| Number of shares | m | 39.97 | 40.43 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.25 | 0.59 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.72 | -1.93 | |||||
| EV/EBITDA LTM | x | 1.30 | 0.37 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -196.04% | -117.76% | |||||
| FCF Yield | % | -139.43% | -51.73% | |||||
| Quality | ||||||||
| ROE | % | -48.93% | -41.05% | |||||
| ROIC | % | -50.85% | -50.85% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -10.74 | -8.69 | |||||
| Net Debt/EBITDA | x | 1.80 | 1.80 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -370.16% | -141.47% | |||||
| Net debt/Equity | x | -0.92 | -0.83 | |||||
| Gross debt/equity | x | 0.03 | 0.04 | |||||
Company overview
Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma. Beyond these, Achilles is also advancing its pipeline with treatments for head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. Initially incorporated as Achilles TX Limited, the company officially adopted the name Achilles Therapeutics Plc in February 2021. Established in 2016, its corporate headquarters are situated in London, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Achilles Therapeutics plc (ACHL)
Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma. Beyond these, Achilles is also advancing its pipeline with treatments for head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. Initially incorporated as Achilles TX Limited, the company officially adopted the name Achilles Therapeutics Plc in February 2021. Established in 2016, its corporate headquarters are situated in London, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free